Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy

Ortolan, E.; Appierto, Valentina; Silvestri, M.; Miceli, Rosalba; Veneroni, Silvia; Folli, Secondo; Pruneri, Giancarlo; Vingiani, Andrea; Belfiore, Antonino; Cappelletti, Vera; Vismara, Marta; Dell'Angelo, Francesca; Cecco, Loris De; Bianchi, Giulia; Braud, Filippo G. De; Daidone, Maria Grazia; Cosimo, Serena Di

doi:10.1016/j.esmoop.2021.100086

Cited by 44 publications

(33 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various studies in neoadjuvantly-treated breast cancer patients found that ctDNA levels and mutations were significantly different between breast cancer subtypes ( 9 , 11 , 40 , 41 ). Expression levels of the proliferation-associated nuclear protein, Ki-67, have also been directly associated with ctDNA characteristics in breast and lung cancers ( 42 – 44 ). Studies assessing ctDNA in non-small cell lung cancer (NSCLC) patients found that ctDNA concentration was correlated with tumor stage, histology, and degree of cytological atypia ( 45 – 47 ).…”

Section: Biological Factors That Most Affect Circulating Tumor Dna Ab...mentioning

confidence: 99%

Blood, Toil, and Taxoteres: Biological Determinants of Treatment-Induced ctDNA Dynamics for Interpreting Tumor Response

Boniface¹,

Spellman²

2022

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Collection and analysis of circulating tumor DNA (ctDNA) is one of the few methods of liquid biopsy that measures generalizable and tumor specific molecules, and is one of the most promising approaches in assessing the effectiveness of cancer care. Clinical assays that utilize ctDNA are commercially available for the identification of actionable mutations prior to treatment and to assess minimal residual disease after treatment. There is currently no clinical ctDNA assay specifically intended to monitor disease response during treatment, partially due to the complex challenge of understanding the biological sources of ctDNA and the underlying principles that govern its release. Although studies have shown pre- and post-treatment ctDNA levels can be prognostic, there is evidence that early, on-treatment changes in ctDNA levels are more accurate in predicting response. Yet, these results also vary widely among cohorts, cancer type, and treatment, likely due to the driving biology of tumor cell proliferation, cell death, and ctDNA clearance kinetics. To realize the full potential of ctDNA monitoring in cancer care, we may need to reorient our thinking toward the fundamental biological underpinnings of ctDNA release and dissemination from merely seeking convenient clinical correlates.

show abstract

Section: Biological Factors That Most Affect Circulating Tumor Dna Ab...mentioning

confidence: 99%

Blood, Toil, and Taxoteres: Biological Determinants of Treatment-Induced ctDNA Dynamics for Interpreting Tumor Response

Boniface¹,

Spellman²

2022

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…Details on ctDNA analysis and predictive/prognostic significance during neoadjuvant therapy have been previously reported (Ortolan et al 2021 ). All clinical and research staff were blinded as to ctDNA and follow-up outcomes, respectively.…”

Section: Methodsmentioning

confidence: 99%

“…Breast cancer cells shed DNA into the blood, and interest in using ctDNA as a sensor to anticipate relapse in advance of clinical manifestation has grown in parallel with the improvement of techniques for its detection (Merker et al 2018 ; Page et al 2021 ). The present work builds on our experience with prospective longitudinal ctDNA monitoring before, during and after neoadjuvant therapy for triple negative breast cancer (Ortolan et al 2021 ). Clinicians were blinded to the results of ctDNA assessment and continued to monitor patients according to their clinical practice.…”

Section: Introductionmentioning

confidence: 99%

“…Clinicians were blinded to the results of ctDNA assessment and continued to monitor patients according to their clinical practice. Here we report the surveillance procedures used in the sample of high-risk early stage breast cancer patients included in the previous study on blood-based genomics (Ortolan et al 2021 ), and the numbers of recurrent disease diagnoses discovered based on symptoms or triggered by follow-up examinations, ctDNA or both in asymptomatic cases.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA

Rocca

Santis

Silvestri

et al. 2022

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

Purpose Physical examinations and annual mammography (minimal follow-up) are as effective as laboratory/imaging tests (intensive follow-up) in detecting breast cancer (BC) recurrence. This statement is now challenged by the availability of new diagnostic tools for asymptomatic cases. Herein, we analyzed current practices and circulating tumor DNA (ctDNA) in monitoring high-risk BC patients treated with curative intent in a comprehensive cancer center. Patients and methods Forty-two consecutive triple negative BC patients undergoing neoadjuvant therapy and surgery were prospectively enrolled. Data from plasma samples and surveillance procedures were analyzed to report the diagnostic pattern of relapsed cases, i.e., by symptoms, follow-up procedures and ctDNA. Results Besides minimal follow-up, 97% and 79% of patients had at least 1 non-recommended imaging and laboratory tests for surveillance purposes. During a median follow-up of 5.1(IQR, 4.1–5.9) years, 13 events occurred (1 contralateral BC, 1 loco-regional recurrence, 10 metastases, and 1 death). Five recurrent cases were diagnosed by intensive follow-up, 5 by symptoms, and 2 incidentally. ctDNA antedated disseminated disease in all evaluable cases excepted two with bone-only and single liver metastases. The mean time from ctDNA detection to suspicious findings at follow-up imaging was 3.81(SD, 2.68), and to definitive recurrence diagnosis 8(SD, 2.98) months. ctDNA was undetectable in the absence of disease and in two suspected cases not subsequently confirmed. Conclusions Some relapses are still symptomatic despite the extensive use of intensive follow-up. ctDNA is a specific test, sensitive enough to detect recurrence before other methods, suitable for clarifying equivocal imaging, and exploitable for salvage therapy in asymptomatic BC survivors.

show abstract

“…The patients in the control group were given laparoscopic radical surgery with the following specific steps. The modified bladder lithotomy position was taken and a cushion was put under the buttocks of the patient, an incision was made at 4 cm away from the upper edge of the nabhi chakra, the casing needle was inserted to establish the pneumoperitoneum, the intraabdominal pressure was maintained between 12 and 15 mmHg, the laparoscopy was inserted to observe the abdominal cavity and the pelvic cavity, and the hysterectomy was performed according to the image displayed by the laparoscopy; after surgery, the wound was rinsed, sutured, disinfected, and bound up [ 16 – 18 ].…”

Section: Methodsmentioning

confidence: 99%

Clinical Effect of Laparoscopic Radical Surgery Combined with Neoadjuvant Chemotherapy in Treating Cervical Cancer and Its Influence on Postoperative Complications and Adverse Reaction Rates

Gong

Liu

2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Background. Cervical cancer, the only gynecological malignancy for which a clear pathogeny has been established, has an incidence rate only second to breast cancer. Objective. In our study, we aim to investigate the clinical effect of laparoscopic radical surgery combined with neoadjuvant chemotherapy in treating cervical cancer and its influence on postoperative complications and adverse reaction rates. Methods. Cervical cancer patients admitted to our hospital from August 2018 to May 2020 were retrospectively analyzed as the research object and divided into the control group and the experimental group by the draw method, with 50 cases in each group. The laparoscopic radical surgery was performed on the control group, and the laparoscopic radical surgery combined with neoadjuvant chemotherapy was performed on the experimental group to compare their effective rates, adverse reaction rates, postoperative complication rates, expression levels of serum tumor necrosis factor-α (TNF-α) and soluble interleukin-2 receptor (SIL-2R) inside the body before surgery and at one week after surgery, quality of life (QLI) scores, and Mental Status Scale in Nonpsychiatric Settings (MSSNS) scores. Results. Compared with the control group, the experimental group obtained significantly higher effective rate and QLI scores ( P < 0.05) and significantly lower adverse reaction rates, postoperative complication rates, expression levels of serum TNF-α and SIL-2R inside the body at one week after surgery, and MSSNS scores ( P < 0.05), with statistical differences; before surgery, the TNF-α and SIL-2R expression levels of the two groups were not significantly different ( P > 0.05), but the levels at one week after surgery were significantly lower than those before, indicating statistical significance ( P < 0.05). Conclusion. The clinical effect of laparoscopic radical surgery combined with neoadjuvant chemotherapy can obviously improve the effective rate of cervical cancer patients and lower the incidence rates of postoperative complications and adverse reactions.

show abstract

Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy

Cited by 44 publications

References 28 publications

Blood, Toil, and Taxoteres: Biological Determinants of Treatment-Induced ctDNA Dynamics for Interpreting Tumor Response

Blood, Toil, and Taxoteres: Biological Determinants of Treatment-Induced ctDNA Dynamics for Interpreting Tumor Response

Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA

Clinical Effect of Laparoscopic Radical Surgery Combined with Neoadjuvant Chemotherapy in Treating Cervical Cancer and Its Influence on Postoperative Complications and Adverse Reaction Rates

Contact Info

Product

Resources

About